International Dermatology COVID-19 Registry
Since the start of the COVID-19 pandemic the ILDS has supported a number of dermatological COVID-19 registries. The ILDS is working together with the American Academy of Dermatology (AAD) to support this International Dermatology COVID-19 Registry, directed by Assistant Professor Esther Freeman from Harvard Medical School in Boston, USA.
Established in April 2020, the Registry is an important tool for collecting dermatologic manifestations of COVID-19 to understand the relationship between the virus and skin. It has provided a rapid and centralised collection point for cases from a global network and supported the dissemination of the findings to the dermatology community and front-line health care workers.
The International Dermatology COVID-19 Registry has now expanded beyond collecting COVID-19 dermatologic manifestations of the virus, and in December 2020 started capturing COVID-19 vaccine-related skin side effects. We encourage healthcare professionals from any country to submit cases to the registry of skin reactions they have seen with any of the COVID-19 vaccines. These may include local vaccine reactions in the arm, more generalised rashes, reactions at site of prior filler injections, or other. Different reactions may occur with different types of COVID-19 vaccines.
The registry is available online through the AAD website at www.aad.org/covidregistry. The ILDS is collaborating with the AAD on this registry with the aim of extending its reach internationally. Cases can be entered by any healthcare worker, including non-dermatologists and non–AAD members, from around the world. Data entry takes 5 to 7 minutes and requires no patient protected health information. Basic patient demographics, dermatologic and medical history, and either new-onset dermatologic conditions in the setting of COVID-19 or vaccine reactions are requested. Photographs are not required. For skin manifestations of the virus, Sars-CoV-2 diagnosis may be based on clinical suspicion alone or laboratory confirmation.
The registry is de-identified, and we do not collect identifiable details about the patient. Our goal is to analyse the data in real time, to better inform vaccination programmes, and the public, about skin reactions in those receiving the COVID-19 vaccine.
The International Dermatology COVID-19 Registry also continues to collect skin manifestations of the virus itself. Thus far, clinicians have entered more than 1200 cases from 42 different countries. Data from the ILDS-supported registry has been used in publications in Lancet Infectious Diseases, JAAD, and BJD among others, and has been cited extensively in the lay press. By coming together, the international dermatologic community is helping to better characterize both the direct effects of the virus, and the ways in which Dermatology, as a field, can help in vaccine roll out.
The registry is an important part of supporting the global community to rapidly share observations without the institutional or national boundaries that often limit scientific collaboration. Ultimately, the success of this international effort depends on the active participation of all health workers caring for patients with COVID-19. Together, we hope to use this registry to compile a more complete and representative case series of potential dermatologic manifestations of COVID-19 and outcomes of established dermatology patients who develop COVID-19.
Any healthcare professional can contribute to the registry by submitting a case here: www.aad.org/covidregistry